Axsome Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
Axsome is a commercial-stage CNS biopharmaceutical company. In 2022 it began U.S. sales of Auvelity for major depressive disorder (MDD) and acquired Sunosi, marketed for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Its principal unapproved programs include AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net product sales | $50.0 million | None reported |
| Cost of product sales | $5.2 million | None reported |
| Research and development expense | $57.9 million | $58.1 million |
| Selling, general and administrative expense | $159.3 million | $66.6 million |
| Net loss | $187.1 million | $130.4 million |
| Net loss per share, basic and diluted | $4.60 | $3.47 |
| Net cash used in operating activities | $116.5 million | $108.2 million |
FY2022 sales comprised $44.8 million from Sunosi, including $0.9 million in ex-U.S. sales, and $5.2 million from Auvelity. The filing does not state an overall operating margin. Advertising expense was $35.3 million; management attributed the increase in SG&A largely to commercialization.
At year-end, cash and cash equivalents were $200.8 million, compared with $86.5 million a year earlier. Total current assets were $245.6 million and current liabilities $96.6 million. The balance sheet reported $95.0 million of term-loan principal ($94.3 million carrying value); contractual-obligation disclosures showed $133.9 million of total term-loan obligations. Stockholders’ equity was $109.6 million.
Material changes versus FY2021
- Product sales began in 2022 following the Auvelity launch and Sunosi acquisition; neither product contributed reported sales in FY2021.
- Net loss increased by $56.7 million, while SG&A rose by $92.7 million. R&D expense was nearly unchanged.
- Operating cash use increased by $8.3 million. Investing cash use was $53.7 million, primarily the $53.0 million Sunosi acquisition payment.
- Financing provided $284.6 million, including $231.8 million net proceeds from at-the-market stock sales and $45.0 million drawn under the Hercules facility. Shares outstanding increased to 43.5 million at year-end from 37.8 million.
Outlook, risks and unusual items
- Management stated that existing cash and remaining committed capital under the amended $350 million Hercules facility were expected to fund the current operating plan into cash-flow positivity. The filing cautions that assumptions may prove wrong and additional financing may be needed. No numerical revenue or earnings guidance was provided.
- In January 2023, Hercules amended the facility, extending maturity to January 2028 (potentially January 2029 if specified revenue targets are met), reducing the stated interest-rate formula, and providing for a further $55 million draw. The debt is secured by substantially all company assets, including intellectual property, and has cash, market-capitalization or revenue-related covenants.
- AXS-07’s migraine NDA received an FDA complete response letter in April 2022. The stated principal issues were chemistry, manufacturing and controls; the FDA did not request new clinical trials, according to the filing. Resubmission was planned, but approval timing remained uncertain.
- AXS-05 met the primary endpoint in the Phase 3 ACCORD Alzheimer’s agitation trial; the Phase 3 ADVANCE-2 trial was ongoing. Topline AXS-12 Phase 3 results were anticipated in the first half of 2023.
- In February 2023, Axsome announced a Sunosi licensing deal with Pharmanovia for Europe and certain Middle East and African countries: €62.0 million upfront, eligibility for up to €94.5 million in milestones, and mid-twenties royalties on territory net sales. These are subsequent events, not FY2022 sales.
- Axsome disclosed receiving a paragraph IV notice from Teva in February 2023 concerning an ANDA for generic Auvelity. Sunosi also carries substantial royalty and milestone commitments. The filing identifies reimbursement and pricing pressure, competition, reliance on third-party manufacturers, clinical and regulatory uncertainty, and financing and debt-covenant risks.
- A securities class action concerning AXS-07 CMC disclosures and related derivative suits were pending; the company reported no other material pending legal proceedings. The financial-statement audit opinion was unqualified, and management and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Quarterly Auvelity and Sunosi sales, prescription trends, net pricing, rebate accruals and commercialization costs; the annual filing does not provide a clear standalone Q4 results set.
- Cash runway against actual operating cash burn, the availability and conditions of undrawn Hercules commitments, and compliance with loan covenants.
- Progress and FDA requirements for the AXS-07 resubmission, and clinical and regulatory milestones for AXS-05, AXS-12, AXS-14 and solriamfetol.
- Teva’s Auvelity ANDA challenge, patent protections and any related litigation developments.
- Sunosi royalties, assumed partner milestones, contingent consideration and the realized economics of the Pharmanovia license.
- Whether commercialization and clinical-development spending, potential dilution and ongoing losses remain consistent with management’s cash-flow-positive outlook.